MedMira Names Robyn Cook as Chief Corporate Officer

HALIFAX, Nov. 4, 2014 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR) announced today that Robyn Cook has been appointed as the Company's Chief Corporate Officer, effective immediately.  Ms. Cook most recently served as MedMira's Senior Director of Corporate Governance.  She will continue in her role as the Company's Corporate Secretary.

Ms. Cook brings a wealth of experience to the position of Chief Corporate Officer, built on over 14 years working in a variety of progressively senior roles at MedMira, spanning corporate governance, compliance, operations, business process and policy development, and human resources.  As Chief Corporate Officer, Ms. Cook will focus on organizational alignment and prioritization of corporate strategy, implementation of industry best practices, and maximizing excellence across all MedMira business units

"Robyn has been a valued member of the Company's senior leadership team for many years, consistently delivering results.  The Board and management team look forward to Robyn's continued contributions to MedMira's growth and success in this new role," said Marvyn Robar, Chairman of the Board, MedMira Inc.  "With hands-on experience and extensive knowledge of many of the key departments within our organization, Robyn is uniquely qualified to strategically connect and align the various parts of our business to drive performance and results."

Prior to joining MedMira, Ms. Cook worked in the energy and education sectors.  She holds a Masters of Business Administration from Saint Mary's University, where the focus of her studies were corporate governance best practices in public life sciences companies.  Ms. Cook also holds a Masters of Science, Nova Scotia Agricultural College and a Bachelor of Science from Dalhousie University.

Ms. Cook's appointment as MedMira's Chief Corporate Officer is subject to final approval of the TSX Venture Exchange.

About MedMira

MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal^â, Multiplo™ and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the first one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE MedMira Inc.